Total
0
Shares
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: AUManufacturing
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medicinal cannabis manufacture Little Green Pharma (LGP) has received a firm purchase order and acquired new land for expansion
  • The company agreed to purchase two properties near its cultivation and manufacturing facilities in South West Western Australia
  • Under the agreement, LGP will purchase the properties for between $5.5 million and $7.5 million in a mixed cash-and-scrip deal
  • LGP is planning to expand its current capacity by the second half of this year
  • Additionally, the company has received a firm purchase order from German pharmaceutical wholesaler Deutsche Medizinalcannabis (DEMECAN)
  • On the market today, LGP is down 1.43 per cent and is trading at 69 cents per share

Medicinal cannabis manufacture Little Green Pharma (LGP) has received a firm purchase order and acquired new land for expansion.

New land

The medicinal cannabis manufacture has agreed to purchase two properties near its cultivation and manufacturing facilities in southwest Western Australia.

Under the agreement, LGP will purchase the land in cash and script payment of between $5.5 million and $7.5 million. The new land covers around 16,000 square metres.

LGP says the new purchase will help service the higher-than-expected international and domestic market demand for LGP cannabis flower medicines.

Through the acquisition, the company can double its indoor cultivation capacity by 3000 square metres within its existing high-security fencing line.

LGP expects to complete the expansion in the second half of this year.

Purchase order

Alongside news of the expansion, the company has received a firm purchase order from German pharmaceutical wholesaler Deutsche Medizinalcannabis (DEMECAN).

The DEMECAN purchase order includes 9000 units of cannabis flower medicines to be delivered in the second quarter of the current 2021 year.

This follows the first commercial shipment of cannabis follower to Germany in February.

The companies have a medicinal cannabis purchase agreement, through which LGP can sell and export up to 1000 kilograms of its dried cannabis flower to DEMECAN each year.

On the market today, LGP is down 1.43 per cent and is trading at 69 cents per share at 12:56 pm AEDT.

LGP by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.